» Articles » PMID: 27627870

Pregnancy-driven Cardiovascular Maternal MiR-29 Plasticity in Obesity

Overview
Journal J Med Primatol
Publisher Wiley
Date 2016 Sep 16
PMID 27627870
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obesity in pregnancy (MO) is a risk factor for maternal and/or fetal cardiovascular system disorders. This study evaluated maternal CVS expression of microRNA-29 family and its target molecules in MO to test the hypotheses: CVS miR-29 concentrations are increased in pregnancy and decreased in MO.

Methods: Non-pregnant (n=4), pregnant obese (POb, n=4), and pregnant non-obese (PnOb, n=4) baboons (Papio spp.) were studied. Maternal left ventricle (LV), left atrium (LA), and aortic arch (AA) were collected at the end of gestation. Expression of MiR-29 and elastin (ELN) mRNA were quantified.

Results: LA miR-29 (a, c) expression was highest in PnOb. In the LV, miR-29b expression trended lower (P=.059) for PnOb animals. ELN mRNA expression correlated positively with miR-29b expression in AA (r=.76, P=.03).

Conclusion: Maternal obesity diminishes miR-29 adaptation to pregnancy. Pharmacologic, tissue-specific targeting of miRNA-29 may represent a strategy for prevention and treatment of MO complications.

Citing Articles

Pregnancy in obese women and mechanisms of increased cardiovascular risk in offspring.

Cochrane A, Murphy M, Ozanne S, Giussani D Eur Heart J. 2024; 45(48):5127-5145.

PMID: 39508438 PMC: 11663486. DOI: 10.1093/eurheartj/ehae671.


Progesterone Changes the Pregnancy-Induced Adaptation of Cardiomyocyte Kv2.1 Channels via MicroRNA-29b.

Liang S, Sun Y, Li L, Long Y, Wang M, Yang H Cardiovasc Ther. 2022; 2022:7145699.

PMID: 35474714 PMC: 9010150. DOI: 10.1155/2022/7145699.

References
1.
Schmiegelow M, Andersson C, Kober L, Andersen S, Olesen J, Jensen T . Prepregnancy obesity and associations with stroke and myocardial infarction in women in the years after childbirth: a nationwide cohort study. Circulation. 2013; 129(3):330-7. DOI: 10.1161/CIRCULATIONAHA.113.003142. View

2.
Li J, Zhang Y, Kuruba R, Gao X, Gandhi C, Xie W . Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol. 2011; 80(1):191-200. PMC: 3127536. DOI: 10.1124/mol.110.068247. View

3.
Corradi D . Atrial fibrillation from the pathologist's perspective. Cardiovasc Pathol. 2014; 23(2):71-84. DOI: 10.1016/j.carpath.2013.12.001. View

4.
Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y . MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 2013; 127(14):1466-75, 1475e1-28. DOI: 10.1161/CIRCULATIONAHA.112.001207. View

5.
Melchiorre K, Sharma R, Thilaganathan B . Cardiac structure and function in normal pregnancy. Curr Opin Obstet Gynecol. 2012; 24(6):413-21. DOI: 10.1097/GCO.0b013e328359826f. View